Table 3.
Parameters of OCT in eyes with neovascular age-related macular degeneration according to subtype of choroidal neovascularization (CNV).
| Type 1 CNV | Type 2 CNV | Type 3 CNV | p-Value | |
|---|---|---|---|---|
| No. of eyes | 34 | 9 | 9 | - |
| Sex (female, %) | 13 (38.2) | 2 (22.2) | 9 (100) | 0.01 * |
| Mean age, years | 73.6 ± 9.2 | 71.56 ± 8.1 | 73.4 ± 8.6 | 0.622 † |
| No. of treatment naive eyes | 2 | 3 | 2 | 0.052 * |
| No. of intravitreal injection | 6.3 ± 4.5 | 5.3 ± 5.7 | 2.7 ± 2.1 | 0.121 † |
| IOP, mmHg | 14.09 ± 2.84 | 15.25 ± 3.96 | 14.77 ± 2.24 | 0.232 † |
| BCVA, logMAR | 0.52 ± 0.43 | 0.53 ± 0.29 | 0.53 ± 0.24 | 0.643 ‡ |
| Disease duration, months | 19.4 ± 14.1 | 13.8 ± 16.3 | 10.7 ± 14.1 | 0.064 ‡ |
| PED max height, μm | 168.7 ± 151.9 | 147.4 ± 78.2 | 180.1 ± 171.5 | 0.822 ‡ |
| PED max width, μm | 2466.7 ± 1,398.9 | 2543.8 ± 1,001.3 | 1733 ± 1,470.8 | 0.310 ‡ |
| Choroidal thickness, μm | 232.5 ± 101.1 | 234.2 ± 90.5 | 139.6 ± 51.1 | 0.016 § |
| Center fovea thickness, μm | 252.6 ± 119.3 | 198.5 ± 75.7 | 349.2 ± 214.8 | 0.422 ‡ |
| CNV area, mm2 | 1.95 ± 1.28 | 3.52 ± 3.41 | 0.51 ± 0.83 | 0.006 ∥ |
| SRF height in eyes with SRF, μm | 100.0 ± 51.9 | 104.1 ± 48.9 | 165.0 ± 96.2 | - |
| SRF existence, no. of eyes | 14 | 6 | 4 | 0.466 * |
BCVA: best-corrected visual acuity; IOP: intraocular pressure. PED: pigment epithelial detachment (serous or vascularized); CNV: choroidal neovascularization; SRF: subretinal fluid. * Fisher’s Exact test; † One-way ANOVA; ‡ Kruskal-Wallis with post-hoc Analysis, § Type 1–Type 3, p = 0.019; ∥ Type 2–Type 3, p = 0.005.